On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula

Table 1 Basic demographic, virological, and clinical features of the 100 patients whose data were used as selection data

	SVR	non-SVR	P value
Number (%)	54 (54.0)	46
Gender (%)
Male	43 (60.6)	28	0.038
Female	9 (34.6)	18
Age
Median	53	57	0.0098
Range	18-72	37-77
Weight (kg)
Median	65.1	60	0.138
Range	42.5-90.5	43.9-86.0
BMI (kg/m2)
Median	23.5	22.9	0.834
Range	17.5-31.8	18.2-31.2
Previous + treatment	22	19	1.000
HCV RNA (KIU/mL)
Median	1889	2263	0.554
Range	140 to < 5000	150 to < 5000
RBC (× 10-4/mL)
Median	469	452	0.0041
Range	319-621	354-552
Hb (g/dL)
Median	15.0	14.1	0.0059
Range	10.9-17.7	11.3-17.2
PLT (× 10-3/mL)
Median	172	159	0.039
Range	84-292	62-270
WBC (/mL)
Median	5000	4850	0.256
Range	3270-8900	2300-9200
NC (/mL)
Median	2550	2549	0.978
Range	1066-4231	1184-5626
AST (IU/L)
Median	54	50	0.898
Range	22-156	24-241
ALT (IU/L)
Median	76	55	0.027
Range	36-311	15-278
PEG-IFN dose (48 wk) (μg/kg per day)
Median	1.43	1.32	0.0043
Range	0.68-1.82	0.52-1.82
RBV dose (48 wk) (mg/kg per day)
Median	10.83	8.39	0.0002
Range	3.42-14.55	2.75-12.64

SVR: Sustained virological response; BMI: Body mass index; RBC: Red blood cell count; Hb: Hemoglobin; PLT: Platelet count; WBC: White blood count; NC: Neutrophil count; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; PEG-IFN dose (48 wk): Total dose of PEG-IFN at 48 wk (μg/kg per wk); RBV dose (48 wk): Total dose of RBV at 48 wk (mg/kg per day).